Search

The authors share their experience with cryosurgical treatment of 38 patients with prostatic cancer (stage T3--in 9 patients, T4--in 29). The technic of cryotherapy is described. The former was employed in patients with complete obstruction of the cervico-urethral segment being nonresponsive to the hormone- and radiotherapy, and also for a life cystostome. Three freezing sessions for 5--15 minutes were conducted with natural warming of the prostate between sessions during 10--12 minutes, and forced warming for 3--4 minutes after the third session. The optimum time of cryoeffect was 5--7 minutes. The postoperative period was smooth, uncomplicated. The process of rejection of the frozen tissues lasted for up to 4--6 weeks, after that a suprapubic drainage was withdrawn and uresis was restored. 32 patients were discharged from the clinic, the survival up to 3 months--in 2, up to 6 months--in 6, up to 1 year--in 4, up to 2 years--in 7, up to 3 years--in 7.

Stage I--II disease was identified in 71 out of 219 patients with nonseminomatous germ cell tumors of the testis. After orchifuniculectomy, polychemotherapy was given to 30 patients while the rest underwent transperitoneal lymphadenectomy. Long-term survival in the polychemotherapy group was 83.3%, in the lymphadenectomy one--95.1%. After excision of the retroperitoneal lymph nodes, the patients' follow-up should include regular assays of such tumor markers as alpha-fetoprotein and chorionic gonadotropin as well as X-ray examination of the chest for at least the first 24 months. Polychemotherapy should not be administered unless tumor dissemination or an increase in tumor marker levels are detected.

The writers present an analysis of the remote results of the combination therapy in 208 patients with cancer of the urinary bladder, depending on the histological form of the tumor. Radical surgery was performed in 193 patients, palliative--in 15. All types of surgical intervention were associated with radiotherapy in the pre- and postoperative period. The survival for 3 years and longer was noted in 153 patients, for 5 years and longer--in 69. Transitional-cell papilloma is characterized by the most favourable prognosis.

The effect of combined treatment was studied in 97 patients with nonseminomatous testicular tumors with regional and distant metastases with regard to the blood serum levels of alpha-fetoprotein and chorionic gonadotropin. The disease stage was found closely correlating with the efficacy of the treatment and the level of tumor markers. Complete remission was observed in 84.2 per cent (16 out of 19) patients with normal marker levels and in 26.8 per cent (11 out of 41) of those in whom both markers levels were raised (p less than 0.05). A continuous follow-up revealed that increased marker levels were the evidence of tumor relapse or metastases in clinically silent patients.